10-K/A: Arrowhead Pharma Amends 10-K, Details Governance & Compensation

Arrowhead Pharmaceuticals filed an amendment to its annual report, providing detailed information on corporate governance, executive compensation, and director changes, alongside significant business and financial updates.

Summary

• Amendment No. 1 to the Annual Report on Form 10-K for the fiscal year ended September 30, 2024, was filed to include Part III information (Items 10-14) related to directors, executive compensation, security ownership, related party transactions, and principal accountant fees.
• The company reported a significant decrease in revenue to $3.6 million in fiscal 2024, down from $240.7 million in fiscal 2023.
• Net loss attributable to Arrowhead Pharmaceuticals, Inc. increased to $599.5 million in fiscal 2024, compared to $205.3 million in fiscal 2023.
• Diluted net loss per share was ($5.00) in fiscal 2024, worsening from ($1.92) in fiscal 2023.
• Cash and investments totaled $681.0 million at September 30, 2024.
• Key business highlights include positive Phase 3 data for plozasiran, submission of a New Drug Application (NDA) for plozasiran with a PDUFA action date of November 18, 2025, and a major collaboration agreement with Sarepta Therapeutics worth up to $10 billion in potential milestones.
• The Sarepta collaboration includes an upfront payment of $500 million cash, a $325 million equity investment, $250 million to be paid in annual installments over five years, and $300 million in near-term payments.
• The company advanced two next-generation RNAi candidates, ARO-INHBE and ARO-ALK7, into upcoming clinical studies for obesity and metabolic diseases.
• Executive compensation saw base salary increases (5-11%) and annual cash bonuses up to 140% of target, with the CEO receiving 120% ($1,152,000).
• The CEO's fiscal 2024 equity award consists of 340,000 performance-based restricted stock units (PRSUs) contingent on a $1 billion cash inflow by June 30, 2025.
• Douglass Given resigned as a director effective December 31, 2024. Javier San Martin (former CMO) and Tracie Oliver (former CCO) departed in February and October 2024, respectively. Daniel Apel is listed as the Chief Financial Officer in the signature block dated October 8, 2025, indicating a change from Kenneth Myszkowski, who was CFO as of January 28, 2025.

Sentiment

Score: 6

Explanation: While the company reported substantial financial losses and a significant drop in revenue for fiscal 2024, these are largely overshadowed by major positive developments in its clinical pipeline and a transformative collaboration agreement with Sarepta Therapeutics. The successful Phase 3 data for plozasiran, its NDA submission, and the multi-billion dollar potential of the Sarepta deal provide strong future growth prospects and financial runway, indicating a strategic focus on long-term value creation despite short-term financial setbacks typical of a clinical-stage biotech. The underperformance in TSR is a concern, but the recent business development activities could reverse this trend.

Positives

• Successful pivotal Phase 3 data from PALISADE study of plozasiran in familial chylomicronemia syndrome (FCS), presented at ESC Congress 2024 and simultaneously published in The New England Journal of Medicine.
• New Drug Application (NDA) for plozasiran submitted to the U.S. FDA on November 16, 2024, and accepted for filing on January 17, 2025, with a PDUFA action date of November 18, 2025, and no advisory committee meeting currently planned.
• Major global collaboration agreement with Sarepta Therapeutics, Inc., valued at $825 million upfront ($500 million cash, $325 million equity investment), with an additional $250 million over five years, $300 million in near-term payments, and up to approximately $10 billion in future potential milestone payments.
• Advancement of two next-generation RNAi-based candidates, ARO-INHBE and ARO-ALK7, into upcoming Phase 1/2a clinical studies for obesity and metabolic diseases, showing potential for improved preservation of lean muscle mass in preclinical studies.
• Amgen completed enrollment in the Phase 3 OCEAN(a) outcomes trial of olpasiran, triggering a $50.0 million milestone payment to the company from Royalty Pharma.
• Initiation of an Expanded Access Program (EAP) for plozasiran for qualifying FCS patients.
• Initiation of a Phase 1/2a clinical trial for ARO-DM1 for type 1 myotonic dystrophy.
• Filing for regulatory clearance to initiate a Phase 1/2a clinical trial for ARO-CFB for complement-mediated renal disease.
• Positive interim clinical data on ARO-RAGE showing high levels of gene knockdown in asthma patients.
• Strong stockholder support for executive compensation program with 94% Say-on-Pay vote in favor.
• CEO's fiscal 2024 equity award of 340,000 PRSUs is entirely performance-based, contingent on a $1 billion cash inflow by June 30, 2025.

Negatives

• Significant decrease in revenue to $3.6 million in fiscal 2024 from $240.7 million in fiscal 2023.
• Substantial increase in net loss to $599.5 million in fiscal 2024 from $205.3 million in fiscal 2023.
• Worsening of diluted net loss per share to ($5.00) in fiscal 2024 from ($1.92) in fiscal 2023.
• Three-year total stockholder return (TSR) at the 28th percentile of the peer group as of September 2024, indicating underperformance relative to peers.
• One inadvertent late filing of a Form 5 for Dr. Lu under Section 16(a) reports.

Risks

• The success of the company's drug candidates and pipeline depends on successful clinical development and regulatory approval, which involves a high degree of risk and sustained effort over many years.
• The realization of value from executive equity awards is dependent on actual operating performance, stock price fluctuations, and continued employment.
• The Sarepta Collaboration is subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act, which could delay or prevent its closing.
• The CEO's performance-based RSU award is contingent on a single performance trigger of a $1 billion cash inflow by June 30, 2025, which introduces a specific financial risk.
• The Compensation Committee's assessment concluded that the performance-based annual incentive compensation plan and long-term equity awards did not appear to create undue risks or encourage excessive risk-taking, but inherent risks in compensation design always exist.

Future Outlook

The company anticipates a PDUFA action date of November 18, 2025, for its plozasiran New Drug Application and is not currently planning an advisory committee meeting. It expects to receive $500 million upfront cash, a $325 million equity investment, $250 million in annual installments over five years, and $300 million in near-term payments from the Sarepta collaboration, with potential for up to $10 billion in future milestone payments and tiered royalties. The CEO's performance-based equity award is tied to achieving a $1 billion cash inflow by June 30, 2025. The company is also advancing new RNAi candidates, ARO-INHBE and ARO-ALK7, into Phase 1/2a clinical trials for obesity and metabolic diseases, and has initiated a Phase 1/2a trial for ARO-DM1 and filed for regulatory clearance for ARO-CFB.

Management Comments

• We believe our executive compensation program is reasonable, competitive, and appropriately balances the goals of attracting, motivating, rewarding, and retaining our executive officers with the objective of aligning their interests with those of our stockholders.
• We believe that, ultimately, the creation of sustainable long-term stockholder value will depend on our ability to successfully bring to market the products we develop or our success in partnering with strategic collaborators to bring them to market.
• The Compensation Committee expects and has observed aggressive performance from the entire executive management team. Our philosophy has been to foster this expectation with reasonably aggressive incentive compensation.
• On the basis of that feedback [from stockholders], and the stockholder vote during our 2024 Annual Meeting of Stockholders, we believe stockholders are pleased with our current compensation approach.

Industry Context

Arrowhead Pharmaceuticals operates in the highly competitive and innovative RNA interference (RNAi) therapeutic space, a growing area for treating genetic diseases by silencing disease-causing genes. The company's focus on expanding RNAi beyond liver targets to lung, muscle, and CNS positions it at the forefront of broadening the technology's application. The significant collaboration with Sarepta Therapeutics, a leader in gene therapy, underscores the industry's increasing interest in RNAi and validates Arrowhead's platform. The development of candidates for cardiometabolic diseases and obesity aligns with major public health challenges and large market opportunities, reflecting a broader industry trend towards addressing these conditions with novel mechanisms. The company's pipeline, including partnered programs with major pharmaceutical companies like Takeda, Amgen, and GSK, demonstrates its ability to attract and maintain strategic alliances, a common and crucial strategy in the high-cost, high-risk drug development industry.

Comparison to Industry Standards

• The company's three-year total stockholder return (TSR) was at the 28th percentile of its peer group as measured in September 2024, indicating underperformance relative to industry benchmarks.
• The average total compensation paid to the company's non-executive directors for service in 2024 is at or below the 60th percentile of the total compensation paid to non-executive directors of its peer group, suggesting competitive but not excessive director compensation.
• The company's executive compensation program is regularly evaluated against a peer group of publicly-held, U.S. biotechnology companies with lead assets in mid to late clinical stage or early commercialization, and market capitalizations between 0.25x to 4.0x the company's market capitalization. Specific peer companies include ACADIA Pharmaceuticals, Insmed, Amicus Therapeutics, Intellia Therapeutics, Apellis Pharmaceuticals, Ionis Pharmaceuticals, Arcus Biosciences, Ironwood Pharmaceuticals, BioCryst Pharmaceuticals, Mirati Therapeutics, Blueprint Medicines, Madrigal Pharmaceuticals, BridgeBio Pharma, REGENXBIO, CRISPR Therapeutics AG, Sarepta Therapeutics, Deciphera Pharmaceuticals, Ultragenyx Pharmaceuticals, Denali Therapeutics, Vir Biotechnology, and Halozyme Therapeutics.

Management Changes

Corporate Governance

Related Party Transactions

• Dr. Bruce Given, Chief Medical Scientist and brother of former Director Douglass Given, received a base salary and bonus of $582,400 in fiscal year 2024 and was awarded 100,000 RSUs (grant date fair value $1,979,000) in January 2025.
• Vincent Anzalone, Vice President, Investor Relations and brother of CEO Christopher Anzalone, received a base salary and bonus of $382,955 in fiscal year 2024 and was awarded 25,000 RSUs (grant date fair value $494,750) in January 2025.

Stakeholder Impact

• Shareholders: Potential for significant long-term value creation through the Sarepta collaboration and pipeline advancements, but short-term financial performance (revenue, net loss, TSR) was poor. Executive compensation is tied to performance and stockholder value.
• Employees: Executive compensation program aims to attract, motivate, and retain highly skilled executives. New inducement plan for equity awards for new hires.
• Patients: Advancement of multiple drug candidates (plozasiran, ARO-INHBE, ARO-ALK7, ARO-DM1, ARO-CFB, ARO-RAGE) offers potential new treatments for severe and rare diseases like FCS, obesity, myotonic dystrophy, and complement-mediated renal disease. Expanded Access Program for plozasiran provides early access to qualifying FCS patients.
• Partners (Sarepta, Takeda, Amgen, GSK): Strengthened collaborations and potential for significant milestone payments and royalties from successful development and commercialization of partnered programs.

Next Steps

• Await PDUFA action date for plozasiran on November 18, 2025.
• Monitor for Hart-Scott Rodino Antitrust Improvements Act clearance for the Sarepta Collaboration.
• Track the progress of Phase 1/2a clinical trials for ARO-INHBE and ARO-ALK7 for obesity and metabolic diseases.
• Monitor the Phase 1/2a clinical trial for ARO-DM1 for type 1 myotonic dystrophy.
• Track the Phase 1/2a clinical trial for ARO-CFB for complement-mediated renal disease.
• Observe the achievement of the CEO's performance-based RSU award, contingent on a $1 billion cash inflow by June 30, 2025.
• Monitor the continued enrollment of certain cohorts in a Phase 1/2 study to trigger $300 million in near-term payments from Sarepta.

Key Dates

Recommendation

While the company reported significant financial losses and a sharp decline in revenue for fiscal year 2024, these are largely expected for a clinical-stage biotechnology company heavily investing in R&D. The substantial collaboration with Sarepta Therapeutics, including a significant upfront cash injection and potential multi-billion dollar milestones, provides a strong financial runway and validates the company's RNAi platform. The positive Phase 3 data for plozasiran and its NDA submission are critical steps towards potential commercialization. However, the stock's underperformance relative to peers (28th percentile TSR) and the inherent risks of drug development, including regulatory hurdles and clinical trial outcomes, warrant a cautious approach. The long-term potential is strong, but the short-term financial metrics are weak, suggesting a 'Hold' recommendation for investors to monitor the execution of the Sarepta deal and the progress of the clinical pipeline.

Keywords

RNAi, biotechnology, pharmaceuticals, drug development, SEC filing, 10-K/A, Arrowhead Pharmaceuticals, plozasiran, FCS, familial chylomicronemia syndrome, Sarepta Therapeutics, collaboration, NDA, FDA, PDUFA, obesity, metabolic diseases, ARO-INHBE, ARO-ALK7, zodasiran, hyperlipidemia, ARO-RAGE, asthma, olpasiran, cardiovascular disease, ARO-DM1, myotonic dystrophy, ARO-CFB, renal disease, corporate governance, executive compensation, financial results